A Study of the Effect of Ascending Single Doses of DG3173 and 300 μg of Octreotide on Human Growth Hormone Levels in Untreated Acromegalics.
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 20
- 主要终点
- Participants With Trough Human Growth Hormone < 2.5 ug/mL
研究概览
简要总结
The study is designed to investigate the safety, tolerability and efficacy of DG3173 in untreated acromegaly patients. Twenty patients received ascending single doses of DG3173 and one dose of octreotide, the current gold standard of medical therapy for acromegaly, with each patient receiving all doses of DG3173 as well as octreotide.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Men, women of non childbearing potential or women of child bearing potential who either abstain from sexual intercourse, have a sterile partner or practice a medically approved double barrier method of contraception
- •Diagnosis of acromegaly of pituitary origin
- •Have age adjusted Insulin like Growth Factor 1 (IGF-1) concentrations ≥1.5 times the upper limit of normal range on two consecutive measurements in the 6 months prior to the first dosing day (including the measurement to be made at screening [Visit 2])
- •Have a random hGH level of ≥5 µg/L in the 6 months prior to or at screening (Visit 2)
- •Have given written informed consent
- •Ability to comply with the requirements of the protocol of the study
排除标准
- •Previous specific treatment for acromegaly in the 6 months prior to screening (Visit 2), including somatostatin analogues (SSAs), surgery, radiotherapy and pegvisomant
- •Treatment with dopamine agonists in the 3 months prior to screening (Visit 2)
- •Uncontrolled hypertension or orthostatic hypotension
- •Type I diabetes mellitus, poorly-controlled type II diabetes mellitus (glycosylated haemoglobin [HbA1c]≥7.5%) and patients requiring insulin treatment
- •Gallstones or gravel that could cause biliary obstruction
- •Hyperprolactinaemia
- •Participation in a clinical study within 60 days prior to screening (Visit 2)
- •Receipt of blood, blood products or plasma derivatives 60 days prior to screening (Visit 2)
- •Pregnancy or lactation
- •A history of active alcohol abuse or drug addiction
- •Positive viral serology screening result for hepatitis B surface antigen, antibodies to hepatitis C virus, or human immunodeficiency virus type 1 and 2
- •Evidence or suspicion of tumour expansion
- •Clinically significant abnormality in screening ECG
- •Any clinically significant abnormal laboratory safety test (biochemistry, haematology and dipstick urinalysis) in the opinion of the Investigator
- •Any disease which in the Investigator's opinion would exclude the patient from the study
研究组 & 干预措施
Octreotide, then ascending DG3173
Interventions: octreotide and DG3173. Eligible patients are to receive 300 µg octreotide as active comparator, followed by four ascending doses of 100 µg, 300 µg, 900 µg and 1800 µg DG3173. All treatments will be administered consecutively to all patients as single subcutaneous bolus injections.
干预措施: octreotide (Drug)
Octreotide, then ascending DG3173
Interventions: octreotide and DG3173. Eligible patients are to receive 300 µg octreotide as active comparator, followed by four ascending doses of 100 µg, 300 µg, 900 µg and 1800 µg DG3173. All treatments will be administered consecutively to all patients as single subcutaneous bolus injections.
干预措施: DG3173 (Drug)
结局指标
主要结局
Participants With Trough Human Growth Hormone < 2.5 ug/mL
时间窗: Pre dose and 0.33, 0.67 hours and 1, 1.5, 2, 3, 4, 5, 6 and 8 hours post dose on each dosing day.
次要结局
未报告次要终点